Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Somaiya Vidyavihar Univ. EGFR compound AE4: sourced facts only. name: "In vitro EGFR kinase assays confirmed their inhibition, with IC50 values of 3.95 µM (AE4), 3.49 µM (AE11), and 4.45 µM (AF11), selectively reduced p-EGFR Tyr1068 and ERK1/2 levels in a dose-dependent manner, while inducing G0/G1 cell-cycle arrest and apoptosis." [PMID:42853331]; target: "In vitro EGFR kinase assays confirmed their inhibition, with IC50 values of 3.95 µM (AE4), 3.49 µM (AE11), and 4.45 µM (AF11), selectively reduced p-EGFR Tyr1068 and ERK1/2 levels in a dose-dependent manner, while inducing G0/G1 cell-cycle arrest and apoptosis." [PMID:42853331]; developer: "Somaiya Institute for Research and Consultancy, Somaiya Vidyavihar University, Vidyavihar (East), Mumbai, India." [PMID:42853331]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Somaiya Vidyavihar Univ. EGFR compound AE4.